上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Aloisine A (Synonyms: RP107)
Aloisine A (RP107) 是一种有效的细胞周期蛋白依赖性激酶 (CDK) 抑制剂,对CDK1/cyclin B、CDK2/cyclin A、CDK2/cyclin E、CDK5/p35 的 IC50 分别为 0.15 μM、0.12 μM、0.4 μM、0.16 μM。Aloisine A 抑制 GSK-3α (IC50=0.5 µM) 和 GSK-3β (IC50=1.5 µM)。Aloisine A 通过独立于 cAMP 的机制,以亚微摩尔亲和力刺激野生型 CFTR 和突变的 CFTR。Aloisine A 具有治疗 CFTR 相关疾病的潜力,包括囊性纤维化研究。
Aloisine A Chemical Structure
CAS No. : 496864-16-5
规格 | 是否有货 | ||
---|---|---|---|
100 mg | 询价 | ||
250 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
生物活性 |
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC50s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC50=0.5 µM) and GSK-3β (IC50=1.5 µM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research[1][2]. |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
|||||||||
体外研究 (In Vitro) |
Aloisine A ininhibits erk1 (IC50=18 µM), erk2 (IC50=22 µM), c-Jun N-terminal kinase (JNK; IC50~3-10 µM). Aloisine A has no effect on protein kinase C α, β1, β2, γ, δ, ε, η, ξ (all IC50>100 µM)[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
|||||||||
分子量 |
267.33 |
|||||||||
Formula |
C16H17N3O |
|||||||||
CAS 号 |
496864-16-5 |
|||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
|||||||||
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
|||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务